CTRI/2009/091/000137进行中（未招募）4 期
Effectiveness and safety of 2 versus 3 doses of HPV Vaccine in preventing cervical cancer: An Indian multi-centre randomized trial.
WHO0 个研究点目标入组 20,000 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Inclusion exclusion criteria:Healthy, ambulant, unmarried girls aged 10-18 years with intact uterus, residing in the selected villagesEligible girl as well as either or both the parents/legal guardian willing to sign a written informed consentExclusion criteria:·
排除标准
- •Inclusion exclusion criteria:Healthy, ambulant, unmarried girls aged 10-18 years with intact uterus, residing in the selected villagesEligible girl as well as either or both the parents/legal guardian willing to sign a written informed consent·Participant having any allergies to medications, food, or any vaccine·Participant who has experienced a serious reaction after receiving any vaccination·Participant having any health problem with asthma, heart disease, lung disease, kidney disease, metabolic disease (e.g., diabetes), epilepsy or any neurological illness, mental or physical disability or blood dyscrasia·Participant who has/had cancer, leukemia, AIDS, or any other immune system problem·Participant who has taken cortisone, prednisone, other steroids, or anticancer drugs, or had radiation treatments in the past 3 months·Participant having any prior history of genital warts or treatment for genital warts·Participant who has received a blood transfusion, any blood products, or been given a medicine called immune (gamma) globulin in the past year·Participant has undergone any surgical procedure for the removal of the uterus·Participant married or engaged to be married in the next 6 months·Participant not willing to use any effective contraception through month 7 of the study if she gets married ·Participant has any plans to permanently relocate from the area prior to the completion of the study or to leave for an extended period of time when study visits would need to be scheduled?.
研究者
相似试验
招募中
2 期
Swinburne Three-dose Psilocybin Assisted Psychotherapy (3PAP): a clinical trial of 2 vs 3 doses of psilocybin-assisted psychotherapy vs psychotherapy with placebo for Treatment-Resistant DepressioTreatment-Resistant DepressionACTRN12623000667617Swinburne University of Technology, Hawthorn160
已完成
不适用
Safety and efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminth infections in humansISRCTN47375023Swiss Tropical Institute (STI) (Switzerland)370
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 19.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-FRovo Nordisk A/S372
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-NLovo Nordisk A/S288
进行中（未招募）
1 期
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.on-alcoholic steatohepatitisMedDRA version: 20.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2016-000685-39-DKovo Nordisk A/S288